Ignite Creation Date:
2025-12-24 @ 1:59 PM
Ignite Modification Date:
2026-06-08 @ 7:40 PM
Study NCT ID:
NCT00663195
Status:
COMPLETED
Last Update Posted:
2008-04-22
First Post:
2008-04-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure
Sponsor:
Tottori University Hospital
Organization:
Study Overview
Official Title:
Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure
Status:
COMPLETED
Status Verified Date:
2008-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels and insulin resistance in patients with chronic heart failure.
Detailed Description:
Myocardial fibrosis is observed in failing hearts. MMPs are considered markers of fibrosis. Recently, circulating MMPs can be measured and are elevated in patients with chronic heart failure (CHF). It has been reported that spironolactone improves myocardial fibrosis in CHF animal models. Therefore, the purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels in patients with chronic heart failure.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: